Validation of the WID-CIN Methylation Test for Detection of Cervical Intraepithelial Neoplasia Grade 3 or Worse in an Independent Cohort
Menée auprès de 119 témoins et 128 patientes présentant une lésion cervicale CIN3+, cette étude évalue la performance du système de score WID-CIN basé sur la méthylation de l'ADN pour identifier les patientes pouvant bénéficier d'une colposcopie
Many cervical screening programmes rely on cytology for triage of high-risk human papillomavirus (hrHPV) positive women. However, cytological triage has variable and often limited sensitivity, and its availability can be restricted in resource-poor settings. The Women's cancer risk IDentification cervical intraepithelial neoplasia (WID-CIN) test is a DNA methylation test shown to have promising diagnostic accuracy as an alternative triage test. In this case–control study, women were recruited from colposcopy clinics in the UK and Greece. Cases were defined as women with histologically confirmed cervical intraepithelial neoplasia Grade 3 or cancer (CIN3+) (n = 128) and controls (n = 119) had histological and/or cytological evidence of normal cervix. The WID-CIN index's accuracy was assessed, and the quality of the index was appraised using a validated biomarker toolkit. The WID-CIN index achieved an area under the curve (AUC) of 0.898 (95%: CI 0.860–0.936) for diagnosis of CIN3+ in all women (irrespective of hrHPV status). In hrHPV positive women only (N = 108), the AUC was 0.875 (95% CI: 0.793–0.956). In contrast to previous work, the WID-CIN maintained high levels of accuracy in women under 30 (N = 57), reporting an AUC of 0.857 (95% CI: 0.762–0.952). Consequently, the WID-CIN index appears to be a highly promising translational biomarker and may provide effective triage to colposcopy clinics. Further validation in large, prospective studies including screening populations and comparison to currently available methods including cytology remain essential next steps.
International Journal of Cancer , article en libre accès, 2026